日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Mass drug administration approved and candidate anthelmintics beginning on larval stage 1 Caenorhabditis elegans are generally potent, suggesting a novel, pre-infective control for helminths

大规模药物管理局批准的候选驱虫药从秀丽隐杆线虫幼虫1期开始使用，通常疗效显著，这表明了一种新的、感染前控制蠕虫的方法。

期刊:PLoS One
影响因子:2.6
doi:10.1371/journal.pone.0346795
Attalla, Sam A; Isaac, Kathryn J; Pfeffer, Morgan; Hockaday, Justin R; Weatherly, Raegan; Asselin, Malia B; Lewis, Allison K; Rai, Viveke; Huff, William A Jr; Long, Mason H; Placide, Tashna; Pearce, Kala R; Nkengbeza, Leopold N; Thurman, Anna K; Cox, Audrey L; Diaz, Giselle Domingo; Carter, Jasmine; Stein, Nathan; Fischer, Sam; Ellis, Brian L
炎症/感染
C. elegans
发表日期：2026
文献求助 收藏

Understory Environmental Conditions Drive Leaf Level-Lipid Biosynthesis in a Deciduous and Evergreen Tree Species

林下环境条件驱动落叶树种和常绿树种叶片脂质生物合成

期刊:Plant Cell and Environment
影响因子:6.3
doi:10.1111/pce.15264
Wang, Zhao; White, Joseph D; Hockaday, William C
发表日期：2025
文献求助 收藏

Freshwater wetlands for flood control: How manipulating the hydroperiod affects plant and invertebrate communities

利用淡水湿地控制洪水：调控水文周期如何影响植物和无脊椎动物群落

期刊:PLoS One
影响因子:2.6
doi:10.1371/journal.pone.0306578
Hockaday, Alyssa C; Leon, Arturo S; Patterson, Kyle; Pennings, Steven C
信号转导
发表日期：2024
文献求助 收藏

The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial

在来那度胺维持治疗的基础上加用伏立诺他治疗所有年龄段新诊断的多发性骨髓瘤患者：来自“Myeloma XI”多中心、开放标签、随机、III期试验的结果

期刊:British Journal of Haematology
影响因子:3.8
doi:10.1111/bjh.18600
Jenner, Matthew W; Pawlyn, Charlotte; Davies, Faith E; Menzies, Tom; Hockaday, Anna; Olivier, Catherine; Jones, John R; Karunanithi, Kamaraj; Lindsay, Jindriska; Kishore, Bhuvan; Cook, Gordon; Drayson, Mark T; Kaiser, Martin F; Owen, Roger G; Gregory, Walter; Cairns, David A; Morgan, Gareth J; Jackson, Graham H
多发性骨髓瘤
骨髓瘤
发表日期：2023
文献求助 收藏

Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study

一项探索性研究：英国国家骨髓瘤研究中心（NCRI）骨髓瘤复发强化试验中，遗传变异与患者自述生活质量和疼痛体验的关联性研究

期刊:Bone Marrow Transplantation
影响因子:5.2
doi:10.1038/s41409-022-01738-y
Snowden, John A; Ahmedzai, Sam H; Cox, Angela; Cairns, David A; Ashcroft, A John; Williams, Cathy; Cavenagh, Jamie D; Hockaday, Anna; Brown, Julia M; Brock, Ian W; Morris, Treen C M; Cook, Gordon
骨髓瘤
发表日期：2022
文献求助 收藏

Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial

奥妥珠单抗作为化疗-免疫疗法后的巩固治疗：英国国家癌症研究所 II/III 期 GALACTIC 试验结果

期刊:British Journal of Haematology
影响因子:3.8
doi:10.1111/bjh.18427
Munir, Talha; Emmerson, Jake; Hockaday, Anna; Oughton, Jamie B; Howard, Dena; Phillips, David; Neilson, Jeff; Pemberton, Nicholas; Paneesha, Shankara; Kennedy, Ben; Rawstron, Andy; Hillmen, Peter
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2022
文献求助 收藏

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial

在初诊多发性骨髓瘤患者中，自体干细胞移植后风险和反应适应性治疗（RADAR（UK-MRA Myeloma XV 试验）：一项 II/III 期随机对照试验的研究方案）

期刊:BMJ Open
影响因子:2.3
doi:10.1136/bmjopen-2022-063037
Royle, Kara-Louise; Coulson, Amy Beth; Ramasamy, Karthik; Cairns, David A; Hockaday, Anna; Quezada, Sergio; Drayson, Mark; Kaiser, Martin; Owen, Roger; Auner, Holger W; Cook, Gordon; Meads, David; Olivier, Catherine; Barnard, Lorna; Lambkin, Rhiannon; Paterson, Andrea; Dawkins, Bryony; Chapman, Mike; Pratt, Guy; Popat, Rakesh; Jackson, Graham; Bygrave, Ceri; Sive, Jonathan; de Tute, Ruth; Chantry, Andrew; Parrish, Christopher; Cook, Mark; Asher, Samir; Yong, Kwee
发育与干细胞
多发性骨髓瘤
骨髓瘤
干细胞
细胞生物学
ADA
发表日期：2022
文献求助 收藏

Evaluating stakeholder engagement in collaborative research: co-producing knowledge for climate resilience

评估利益相关者在合作研究中的参与度：共同创造气候适应能力知识

期刊:
影响因子:
doi:10.1007/s42532-022-00124-8
Singletary, Loretta; Koebele, Elizabeth; Evans, William; Copp, Christopher J; Hockaday, Shelby; Rego, Jesse Jo
发表日期：2022
文献求助 收藏

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial

卡非佐米、来那度胺、地塞米松和环磷酰胺（KRdc）作为适合移植的新诊断多发性骨髓瘤患者（骨髓瘤XI+）的诱导治疗：一项开放标签随机对照试验的中期分析

期刊:PLoS Medicine
影响因子:9.9
doi:10.1371/journal.pmed.1003454
Jackson, Graham H; Pawlyn, Charlotte; Cairns, David A; de Tute, Ruth M; Hockaday, Anna; Collett, Corinne; Jones, John R; Kishore, Bhuvan; Garg, Mamta; Williams, Cathy D; Karunanithi, Kamaraj; Lindsay, Jindriska; Rocci, Alberto; Snowden, John A; Jenner, Matthew W; Cook, Gordon; Russell, Nigel H; Drayson, Mark T; Gregory, Walter M; Kaiser, Martin F; Owen, Roger G; Davies, Faith E; Morgan, Gareth J
骨髓瘤
多发性骨髓瘤
发表日期：2021
文献求助 收藏

Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials project

适应性临床试验的成本和人员配备需求：来自“适应性试验成本核算项目”的定量和定性结果

期刊:BMC Medicine
影响因子:8.3
doi:10.1186/s12916-021-02124-z
Wilson, Nina; Biggs, Katie; Bowden, Sarah; Brown, Julia; Dimairo, Munyaradzi; Flight, Laura; Hall, Jamie; Hockaday, Anna; Jaki, Thomas; Lowe, Rachel; Murphy, Caroline; Pallmann, Philip; Pilling, Mark A; Snowdon, Claire; Sydes, Matthew R; Villar, Sofía S; Weir, Christopher J; Welburn, Jessica; Yap, Christina; Maier, Rebecca; Hancock, Helen; Wason, James M S
发表日期：2021
文献求助 收藏